<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5474">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129245</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU FAMPLAN SFP3-7</org_study_id>
    <nct_id>NCT01129245</nct_id>
  </id_info>
  <brief_title>The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation</brief_title>
  <official_title>The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect that Celebrex (a COX-2 inhibitor and
      non-steroidal anti-inflammatory drug) has on ovulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Menstrual Length When Taken After Ovulation: Extended Luteal Phase</measure>
    <time_frame>Completion of study (1 year)</time_frame>
    <safety_issue>No</safety_issue>
    <description>average menstrual cycle length in days during active drug exposure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Luteal Phase Progesterone Levels</measure>
    <time_frame>completion of study (1 year)</time_frame>
    <safety_issue>No</safety_issue>
    <description>progesterone levels during study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Ovulation</condition>
  <condition>Luteal Development</condition>
  <arm_group>
    <arm_group_label>Placebo first, then celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control menstrual cycle, placebo menstrual cycle, celecoxib cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control menstrual cycle, celecoxib menstrual cycle, placebo menstrual cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celebrex</intervention_name>
    <description>400 mg PO daily intermittently based on hormone and ultrasound findings</description>
    <arm_group_label>Placebo first, then celecoxib</arm_group_label>
    <arm_group_label>Celecoxib first, then placebo</arm_group_label>
    <other_name>celecoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo first, then celecoxib</arm_group_label>
    <arm_group_label>Celecoxib first, then placebo</arm_group_label>
    <other_name>identical placebo to celebrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-35

          -  Currently NOT using hormonal contraception

          -  Cycle length between 26-34 days

          -  General good health (specifically no hx of: diabetes, cardiac problems,
             moderate/severe heart burn (GERD), obesity (BMI &gt; 30), hypertension (BP &gt; 130/80)

          -  Willing and able to agree to randomization and informed consent

          -  Willing and able to use a menstrual diary to chart bleeding Serum progesterone &gt; 3
             ng/ml (from cycle day 18-25)

          -  Willing and able to return to clinic for bi-weekly for blood tests and ultrasounds
             throughout cycles 2, 3 &amp; 5

        Exclusion Criteria:

          -  Diabetes

          -  Cardiac disease

          -  Moderate to severe heart burn (or GERD) Obesity (BMI &gt; 30) Hypertension (BP &gt; 130/80)

          -  Allergy to NSAIDS

          -  Currently pregnant or trying to conceive

          -  Polycystic Ovarian Syndrome

          -  Use of hormonal contraception (participants can use barrier methods, spermicide,
             female or male sterilization, copper intrauterine device, abstinence, or have female
             partners
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Edelman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 2, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2010</firstreceived_date>
  <firstreceived_results_date>April 7, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alison Edelman</investigator_full_name>
    <investigator_title>Assistant Professor SM.OB/GYN Generalist Division</investigator_title>
  </responsible_party>
  <keyword>Celebrex</keyword>
  <keyword>prostoglandin inhibitor</keyword>
  <keyword>ovulation</keyword>
  <keyword>emergency contraception</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo First, Then Celecoxib</title>
          <description>receive celebrex based on hormone and ultrasound findings and timing of menstrual cycle
celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Celecoxib First, Then Placebo</title>
          <description>receive celebrex based on hormone and ultrasound findings and timing of menstrual cycle
celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>healthy reproductive-aged women with regular cycles, not currently using or needing hormonal contraception</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo First, Then Celecoxib</title>
          <description>control menstrual cycle, placebo menstrual cycle, and then celecoxib menstrual cycle</description>
        </group>
        <group group_id="B2">
          <title>Celecoxib First, Then Placebo</title>
          <description>control menstrual cycle, celecoxib menstrual cycle, placebo menstrual cycle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27.3" lower_limit="18" upper_limit="35"/>
                <measurement group_id="B2" value="28.8" lower_limit="18" upper_limit="35"/>
                <measurement group_id="B3" value="27.8" lower_limit="18" upper_limit="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Menstrual Length When Taken After Ovulation: Extended Luteal Phase</title>
        <description>average menstrual cycle length in days during active drug exposure</description>
        <time_frame>Completion of study (1 year)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Celebrex</title>
            <description>receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results
celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>received placebo during menstrual cycle</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Menstrual Length When Taken After Ovulation: Extended Luteal Phase</title>
            <description>average menstrual cycle length in days during active drug exposure</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28.5" spread="2.5"/>
                  <measurement group_id="O2" value="27.8" spread="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Luteal Phase Progesterone Levels</title>
        <description>progesterone levels during study</description>
        <time_frame>completion of study (1 year)</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Celebrex</title>
          <description>receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results
celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>received placebo drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Edelman</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>503-494-5949</phone>
      <email>edelmana@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
